{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,23]],"date-time":"2026-08-23T18:15:34Z","timestamp":1787508934822,"version":"build-2736575974"},"reference-count":54,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2024,2,23]],"date-time":"2024-02-23T00:00:00Z","timestamp":1708646400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Public Health"],"abstract":"<jats:sec>\n                    <jats:title>Introduction<\/jats:title>\n                    <jats:p>Rotavirus-associated diarrheal diseases significantly burden healthcare systems, particularly affecting infants under five years. Both Rotarix\u2122 (RV1) and RotaTeq\u2122 (RV5) vaccines have been effective but have distinct application schedules and limited interchangeability data. This study aims to provide evidence on the immunogenicity, reactogenicity, and safety of mixed RV1-RV5 schedules compared to their standard counterparts.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>This randomized, double-blind study evaluated the non-inferiority in terms of immunogenicity of mixed rotavirus vaccine schedules compared to standard RV1 and RV5 schedules in a cohort of 1,498 healthy infants aged 6 to 10\u2009weeks. Participants were randomly assigned to one of seven groups receiving various combinations of RV1, and RV5. Standard RV1 and RV5 schedules served as controls of immunogenicity, reactogenicity, and safety analysis. IgA antibody levels were measured from blood samples collected before the first dose and one month after the third dose. Non-inferiority was concluded if the reduction in seroresponse rate in the mixed schemes, compared to the standard highest responding scheme, did not exceed the non-inferiority margin of \u22120.10. Reactogenicity traits and adverse events were monitored for 30\u2009days after each vaccination and analyzed on the entire cohort.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Out of the initial cohort, 1,365 infants completed the study. Immunogenicity analysis included 1,014 infants, considering IgA antibody titers \u226520\u2009U\/mL as seropositive. Mixed vaccine schedules demonstrated non-inferiority to standard schedules, with no significant differences in immunogenic response. Safety profiles were comparable across all groups, with no increased incidence of serious adverse events or intussusception.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>The study confirms that mixed rotavirus vaccine schedules are non-inferior to standard RV1 and RV5 regimens in terms of immunogenicity and safety. This finding supports the flexibility of rotavirus vaccination strategies, particularly in contexts of vaccine shortage or logistic constraints. These results contribute to the global effort to optimize rotavirus vaccination programs for broader and more effective pediatric coverage.<\/jats:p>\n                    <jats:p>\n                      <jats:bold>Clinical trial registration<\/jats:bold>\n                      :\n                      <jats:ext-link>ClinicalTrials.gov<\/jats:ext-link>\n                      , NCT02193061.\n                    <\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fpubh.2024.1356932","type":"journal-article","created":{"date-parts":[[2024,2,22]],"date-time":"2024-02-22T23:27:48Z","timestamp":1708644468000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":3,"title":["Immunogenicity of RV1 and RV5 vaccines administered in standard and interchangeable mixed schedules: a randomized, double-blind, non-inferiority clinical trial in Mexican infants"],"prefix":"10.3389","volume":"12","author":[{"given":"Mercedes","family":"Mac\u00edas-Parra","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patricia","family":"Vidal-V\u00e1zquez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jes\u00fas","family":"Reyna-Figueroa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Miguel \u00c1ngel","family":"Rodr\u00edguez-Weber","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hortensia","family":"Moreno-Mac\u00edas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"In\u00e9s","family":"Hern\u00e1ndez-Benavides","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sof\u00eda","family":"Fortes-Guti\u00e9rrez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vesta Louise","family":"Richardson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paola","family":"V\u00e1zquez-C\u00e1rdenas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2024,2,23]]},"reference":[{"key":"ref1","doi-asserted-by":"publisher","first-page":"958","DOI":"10.1001\/jamapediatrics.2018.1960","article-title":"Rotavirus vaccination and the global burden of rotavirus diarrhea among children younger than 5 years","volume":"172","author":"Troeger","year":"2018","journal-title":"JAMA Pediatr"},{"key":"ref2","doi-asserted-by":"publisher","first-page":"166","DOI":"10.1186\/s12985-022-01898-9","article-title":"Global burden and trends of rotavirus infection-associated deaths from 1990 to 2019: an observational trend study","volume":"19","author":"Du","year":"2022","journal-title":"Virol J"},{"key":"ref3","doi-asserted-by":"publisher","first-page":"529","DOI":"10.1080\/14760584.2020.1775079","article-title":"An overview of rotavirus vaccination programs in developing countries","volume":"19","author":"Hallowell","year":"2020","journal-title":"Expert Rev Vaccines"},{"key":"ref4","doi-asserted-by":"publisher","first-page":"17083","DOI":"10.1038\/nrdp.2017.83","article-title":"Rotavirus infection","volume":"3","author":"Crawford","year":"2017","journal-title":"Nat Rev Dis Primers"},{"key":"ref5","doi-asserted-by":"publisher","first-page":"687","DOI":"10.1586\/14760584.2014.905747","article-title":"Rotavirus vaccination in central American children","volume":"13","author":"Ulloa-Gutierrez","year":"2014","journal-title":"Expert Rev Vaccines"},{"key":"ref6","doi-asserted-by":"publisher","first-page":"299","DOI":"10.1056\/NEJMoa0905211","article-title":"Effect of rotavirus vaccination on death from childhood diarrhea in Mexico","volume":"362","author":"Richardson","year":"2010","journal-title":"N Engl J Med"},{"key":"ref7","doi-asserted-by":"publisher","first-page":"e1001024","DOI":"10.1371\/journal.pmed.1001024","article-title":"Decline in diarrhea mortality and admissions after routine childhood rotavirus immunization in Brazil: a time-series analysis","volume":"8","author":"do Carmo","year":"2011","journal-title":"PLoS Med"},{"key":"ref8","doi-asserted-by":"publisher","first-page":"e206","DOI":"10.1016\/j.ijid.2010.11.007","article-title":"Impact of rotavirus vaccination on childhood deaths from diarrhea in Brazil","volume":"15","author":"Lanzieri","year":"2011","journal-title":"Int J Infect Dis"},{"key":"ref9","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1056\/NEJMoa052664","article-title":"Safety and efficacy of a pentavalent human-bovine (WC3) reassortant rotavirus vaccine","volume":"354","author":"Vesikari","year":"2006","journal-title":"N Engl J Med"},{"key":"ref10","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1056\/NEJMoa052434","article-title":"Safety and efficacy of an attenuated vaccine against severe rotavirus gastroenteritis","volume":"354","author":"Ruiz-Palacios","year":"2006","journal-title":"N Engl J Med"},{"key":"ref11","doi-asserted-by":"publisher","first-page":"e41720","DOI":"10.1371\/journal.pone.0041720","article-title":"Understanding reduced rotavirus vaccine efficacy in low socio-economic settings","volume":"7","author":"Lopman","year":"2012","journal-title":"PLoS One"},{"key":"ref12","doi-asserted-by":"publisher","first-page":"840","DOI":"10.1093\/cid\/cix369","article-title":"Effectiveness of rotavirus vaccination: a systematic review of the first decade of global Postlicensure data, 2006-2016","volume":"65","author":"Jonesteller","year":"2017","journal-title":"Clin Infect Dis"},{"key":"ref13","doi-asserted-by":"publisher","first-page":"S39","DOI":"10.1086\/605035","article-title":"Oral rotavirus vaccines: how well will they work where they are needed most?","volume":"200","author":"Patel","year":"2009","journal-title":"J Infect Dis"},{"key":"ref14","doi-asserted-by":"publisher","first-page":"A36","DOI":"10.1016\/j.vaccine.2011.09.120","article-title":"Efficacy of human rotavirus vaccine against severe gastroenteritis in Malawian children in the first two years of life: a randomized, double-blind, placebo controlled trial","volume":"30","author":"Cunliffe","year":"2012","journal-title":"Vaccine"},{"key":"ref15","doi-asserted-by":"publisher","first-page":"874","DOI":"10.1097\/INF.0b013e3181782780","article-title":"Concomitant use of the oral pentavalent human-bovine reassortant rotavirus vaccine and oral poliovirus vaccine","volume":"27","author":"Ciarlet","year":"2008","journal-title":"Pediatr Infect Dis J"},{"key":"ref16","doi-asserted-by":"publisher","first-page":"1678","DOI":"10.1093\/infdis\/jiw023","article-title":"A randomized, controlled trial of the impact of alternative dosing schedules on the immune response to human rotavirus vaccine in rural Ghanaian infants","volume":"213","author":"Armah","year":"2016","journal-title":"J Infect Dis"},{"key":"ref17","doi-asserted-by":"publisher","first-page":"163","DOI":"10.1046\/j.1529-8027.2002.02010.x","article-title":"Postvaccinal inflammatory neuropathy: peripheral nerve biopsy in 3 cases","volume":"7","author":"Vital","year":"2002","journal-title":"J Peripher Nerv Syst"},{"key":"ref18","doi-asserted-by":"publisher","first-page":"A110","DOI":"10.1016\/j.vaccine.2014.04.079","article-title":"Efficacy of a monovalent human-bovine (116E) rotavirus vaccine in Indian children in the second year of life","volume":"32","author":"Bhandari","year":"2014","journal-title":"Vaccine"},{"key":"ref19","doi-asserted-by":"publisher","first-page":"1121","DOI":"10.1056\/NEJMoa1609462","article-title":"Efficacy of a low-cost, heat-stable oral rotavirus vaccine in Niger","volume":"376","author":"Isanaka","year":"2017","journal-title":"N Engl J Med"},{"key":"ref20","doi-asserted-by":"publisher","first-page":"1191","DOI":"10.1016\/S1473-3099(22)00161-X","article-title":"Safety and immunogenicity of the Rotavac and Rotasiil rotavirus vaccines administered in an interchangeable dosing schedule among healthy Indian infants: a multicentre, open-label, randomised, controlled, phase 4, non-inferiority trial","volume":"22","author":"Kanungo","year":"2022","journal-title":"Lancet Infect Dis"},{"key":"ref21","doi-asserted-by":"publisher","first-page":"3623","DOI":"10.1080\/21645515.2021.1936859","article-title":"15-year experience with rotavirus vaccination in Mexico: a systematic literature review","volume":"17","author":"Guzman-Holst","year":"2021","journal-title":"Hum Vaccin Immunother"},{"key":"ref22","doi-asserted-by":"publisher","first-page":"529","DOI":"10.1038\/nrmicro1692","article-title":"Rotavirus vaccines: recent developments and future considerations","volume":"5","author":"Angel","year":"2007","journal-title":"Nat Rev Microbiol"},{"key":"ref23","doi-asserted-by":"publisher","first-page":"e20152603","DOI":"10.1542\/peds.2015-2603","article-title":"Safety and immunogenicity of sequential rotavirus vaccine schedules","volume":"137","author":"Libster","year":"2016","journal-title":"Pediatrics"},{"key":"ref24","doi-asserted-by":"publisher","first-page":"1426","DOI":"10.1016\/j.vaccine.2015.01.072","article-title":"Comparing vaccines: a systematic review of the use of the non-inferiority margin in vaccine trials","volume":"33","author":"Donken","year":"2015","journal-title":"Vaccine"},{"key":"ref25","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1093\/infdis\/159.1.79","article-title":"Effects of antibody to rotavirus on protection of adults challenged with a human rotavirus","volume":"159","author":"Ward","year":"1989","journal-title":"J Infect Dis"},{"key":"ref26","doi-asserted-by":"publisher","first-page":"381","DOI":"10.1016\/S0264-410X(97)00210-7","article-title":"Safety and immunogenicity of live, attenuated human rotavirus vaccine 89-12","volume":"16","author":"Bernstein","year":"1998","journal-title":"Vaccine"},{"key":"ref27","doi-asserted-by":"publisher","first-page":"447","DOI":"10.1128\/jcm.19.4.447-452.1984","article-title":"Estimation of rotavirus immunoglobulin G antibodies in human serum samples by enzyme-linked immunosorbent assay: expression of results as units derived from a standard curve","volume":"19","author":"Bishop","year":"1984","journal-title":"J Clin Microbiol"},{"key":"ref28","doi-asserted-by":"publisher","first-page":"440","DOI":"10.1093\/infdis\/161.3.440","article-title":"Protection of adults rechallenged with a human rotavirus","volume":"161","author":"Ward","year":"1990","journal-title":"J Infect Dis"},{"key":"ref29","author":"Karla","year":"2012"},{"key":"ref30","doi-asserted-by":"publisher","first-page":"287","DOI":"10.1016\/S0140-6736(98)12106-2","article-title":"Efficacy of live, attenuated, human rotavirus vaccine 89-12 in infants: a randomised placebo-controlled trial","volume":"354","author":"Bernstein","year":"1999","journal-title":"Lancet"},{"key":"ref31","doi-asserted-by":"publisher","first-page":"2718","DOI":"10.1016\/j.vaccine.2005.12.048","article-title":"Immunity and correlates of protection for rotavirus vaccines","volume":"24","author":"Franco","year":"2006","journal-title":"Vaccine"},{"key":"ref32","doi-asserted-by":"publisher","first-page":"505","DOI":"10.4161\/hv.27097","article-title":"Association of serum anti-rotavirus immunoglobulin a antibody seropositivity and protection against severe rotavirus gastroenteritis: analysis of clinical trials of human rotavirus vaccine","volume":"10","author":"Cheuvart","year":"2014","journal-title":"Hum Vaccin Immunother"},{"key":"ref33","doi-asserted-by":"publisher","first-page":"284","DOI":"10.1093\/infdis\/jit166","article-title":"A systematic review of anti-rotavirus serum IgA antibody titer as a potential correlate of rotavirus vaccine efficacy","volume":"208","author":"Patel","year":"2013","journal-title":"J Infect Dis"},{"key":"ref34","doi-asserted-by":"publisher","first-page":"309","DOI":"10.1093\/infdis\/jiaa068","article-title":"Postvaccination serum antirotavirus immunoglobulin a as a correlate of protection against rotavirus gastroenteritis across settings","volume":"222","author":"Baker","year":"2020","journal-title":"J Infect Dis"},{"key":"ref35","first-page":"1","article-title":"Prevention of rotavirus gastroenteritis among infants and children: recommendations of the Advisory Committee on Immunization Practices (ACIP)","volume":"58","author":"Cortese","year":"2009","journal-title":"MMWR Recomm Rep"},{"key":"ref36","doi-asserted-by":"publisher","first-page":"A117","DOI":"10.1016\/j.vaccine.2014.03.069","article-title":"Evaluation of safety and immunogenicity of a live attenuated tetravalent (G1-G4) bovine-human Reassortant rotavirus vaccine (BRV-TV) in healthy Indian adults and infants","volume":"32","author":"Dhingra","year":"2014","journal-title":"Vaccine"},{"key":"ref37","doi-asserted-by":"publisher","first-page":"1870395","DOI":"10.1080\/21645515.2020.1870395","article-title":"Established and new rotavirus vaccines: a comprehensive review for healthcare professionals","volume":"18","author":"Vetter","year":"2022","journal-title":"Hum Vaccin Immunother"},{"key":"ref38","doi-asserted-by":"publisher","first-page":"CD008521","DOI":"10.1002\/14651858.CD008521.pub5","article-title":"Vaccines for preventing rotavirus diarrhoea: vaccines in use","volume":"2019","author":"Soares-Weiser","year":"2019","journal-title":"Cochrane Database Syst Rev"},{"key":"ref39","doi-asserted-by":"publisher","first-page":"532","DOI":"10.4161\/hv.6.7.11278","article-title":"Performance of rotavirus vaccines in developed and developing countries","volume":"6","author":"Jiang","year":"2010","journal-title":"Hum Vaccin"},{"key":"ref40","doi-asserted-by":"publisher","first-page":"1421","DOI":"10.4161\/hv.28284","article-title":"Bayesian network meta-analysis suggests a similar effectiveness between a monovalent and a pentavalent rotavirus vaccine: a preliminary report of re-analyses of data from a Cochrane database systematic review","volume":"10","author":"Masato","year":"2014","journal-title":"Hum Vaccin Immunother"},{"key":"ref41","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/mi.2014.114","article-title":"Correlates of protection against human rotavirus disease and the factors influencing protection in low-income settings","volume":"8","author":"Clarke","year":"2015","journal-title":"Mucosal Immunol"},{"key":"ref42","doi-asserted-by":"publisher","first-page":"e1195","DOI":"10.1016\/S2214-109X(20)30262-X","article-title":"Real-world effectiveness of rotavirus vaccines, 2006-19: a literature review and meta-analysis","volume":"8","author":"Burnett","year":"2020","journal-title":"Lancet Glob Health"},{"key":"ref43","doi-asserted-by":"publisher","first-page":"145","DOI":"10.1080\/14760584.2018.1418665","article-title":"Decreased performance of live attenuated, oral rotavirus vaccines in low-income settings: causes and contributing factors","volume":"17","author":"Velasquez","year":"2018","journal-title":"Expert Rev Vaccines"},{"key":"ref44","doi-asserted-by":"publisher","first-page":"3659","DOI":"10.4161\/hv.34361","article-title":"Correlates of protection for rotavirus vaccines: possible alternative trial endpoints, opportunities, and challenges","volume":"10","author":"Angel","year":"2014","journal-title":"Hum Vaccin Immunother"},{"key":"ref45","doi-asserted-by":"publisher","first-page":"5670","DOI":"10.1016\/j.vaccine.2015.08.027","article-title":"Association between mixed rotavirus vaccination types of infants and rotavirus acute gastroenteritis","volume":"33","author":"Mohammed","year":"2015","journal-title":"Vaccine"},{"key":"ref46","doi-asserted-by":"publisher","first-page":"708","DOI":"10.1001\/jamapediatrics.2016.0014","article-title":"Evaluation of effectiveness of mixed rotavirus vaccine course for rotavirus gastroenteritis","volume":"170","author":"Payne","year":"2016","journal-title":"JAMA Pediatr"},{"key":"ref47","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1093\/cid\/ciab895","article-title":"Plasma rotavirus-specific IgA and risk of rotavirus vaccine failure in infants in Malawi","volume":"75","author":"Pollock","year":"2022","journal-title":"Clin Infect Dis"},{"key":"ref48","doi-asserted-by":"publisher","first-page":"1602","DOI":"10.1086\/317619","article-title":"Serum antibody as a marker of protection against natural rotavirus infection and disease","volume":"182","author":"Velazquez","year":"2000","journal-title":"J Infect Dis"},{"key":"ref49","doi-asserted-by":"publisher","first-page":"1022","DOI":"10.1056\/NEJM199610033351404","article-title":"Rotavirus infection in infants as protection against subsequent infections","volume":"335","author":"Velazquez","year":"1996","journal-title":"N Engl J Med"},{"key":"ref50","doi-asserted-by":"publisher","first-page":"186","DOI":"10.1093\/cid\/ciy076","article-title":"Rotavirus-specific immunoglobulin a responses are impaired and serve as a suboptimal correlate of protection among infants in Bangladesh","volume":"67","author":"Lee","year":"2018","journal-title":"Clin Infect Dis"},{"key":"ref51","year":"2021"},{"key":"ref52","doi-asserted-by":"publisher","first-page":"217","DOI":"10.2223\/JPED.1600","article-title":"Safety, immunogenicity, and protective efficacy of two doses of RIX4414 live attenuated human rotavirus vaccine in healthy infants","volume":"83","author":"Araujo","year":"2007","journal-title":"J Pediatr"},{"key":"ref53","doi-asserted-by":"publisher","first-page":"78","DOI":"10.1016\/j.vaccine.2020.09.019","article-title":"Risk of intussusception after monovalent rotavirus vaccine (Rotavac) in Indian infants: a self-controlled case series analysis","volume":"39","year":"2021","journal-title":"Vaccine"},{"key":"ref54","doi-asserted-by":"publisher","first-page":"561","DOI":"10.1016\/j.meegid.2014.10.008","article-title":"Strain diversity plays no major role in the varying efficacy of rotavirus vaccines: an overview","volume":"28","author":"Daniel","year":"2014","journal-title":"Infect Genet Evol"}],"container-title":["Frontiers in Public Health"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fpubh.2024.1356932\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,2,22]],"date-time":"2024-02-22T23:27:52Z","timestamp":1708644472000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fpubh.2024.1356932\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,2,23]]},"references-count":54,"alternative-id":["10.3389\/fpubh.2024.1356932"],"URL":"https:\/\/doi.org\/10.3389\/fpubh.2024.1356932","relation":{},"ISSN":["2296-2565"],"issn-type":[{"value":"2296-2565","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,2,23]]},"article-number":"1356932"}}